Your browser doesn't support javascript.
loading
Prognostic impact of TP53 mutation, monosomal karyotype, and prior myeloid disorder in nonremission acute myeloid leukemia at allo-HSCT.
Najima, Yuho; Sadato, Daichi; Harada, Yuka; Oboki, Keisuke; Hirama, Chizuko; Toya, Takashi; Doki, Noriko; Haraguchi, Kyoko; Yoshifuji, Kota; Akiyama, Megumi; Inamoto, Kyoko; Igarashi, Aiko; Kobayashi, Takeshi; Kakihana, Kazuhiko; Okuyama, Yoshiki; Sakamaki, Hisashi; Harada, Hironori; Ohashi, Kazuteru.
Afiliación
  • Najima Y; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Sadato D; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Harada Y; Clinical Research Support Center, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Oboki K; Center for Medical Research Cooperation, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
  • Hirama C; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan. yharada@cick.jp.
  • Toya T; Clinical Research Support Center, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan. yharada@cick.jp.
  • Doki N; Center for Medical Research Cooperation, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
  • Haraguchi K; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Yoshifuji K; Clinical Research Support Center, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Akiyama M; Center for Medical Research Cooperation, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
  • Inamoto K; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Igarashi A; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Kobayashi T; Division of Transfusion and Cell Therapy, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Kakihana K; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Okuyama Y; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Sakamaki H; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Harada H; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Ohashi K; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Bone Marrow Transplant ; 56(2): 334-346, 2021 02.
Article en En | MEDLINE | ID: mdl-32760007
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Trasplante de Células Madre Hematopoyéticas Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Bone Marrow Transplant Asunto de la revista: TRANSPLANTE Año: 2021 Tipo del documento: Article País de afiliación: Japón
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Trasplante de Células Madre Hematopoyéticas Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Bone Marrow Transplant Asunto de la revista: TRANSPLANTE Año: 2021 Tipo del documento: Article País de afiliación: Japón